Galectin Therapeutics Inc (NASDAQ:GALT)

4.56
Delayed Data
As of May 18
 +0.18 / +4.11%
Today’s Change
1.28
Today|||52-Week Range
6.74
+36.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$151.0M

Company Description

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Contact Information

Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
P:(678) 620-3186
Investor Relations:

Employees

Shareholders

Other institutional8.48%
Mutual fund holders4.08%
Individual stakeholders20.55%

Top Executives

Peter G. TraberPresident, CEO & Chief Medical Officer
Harold H. ShlevinChief Operating Officer & Secretary
Jack W. CallicuttChief Financial & Accounting Officer
Adam E. AllgoodExecutive Director-Clinical Development
Eliezer ZomerExecutive VP-Manufacturing & Product Development